Trial Profile
An Open-label Study to Investigate the Safety, Tolerability and Efficacy of a Single 6-hour Intravenous Infusion of AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Diazepinomicin (Primary)
- Indications Telomeric 22q13 Monosomy Syndrome
- Focus Adverse reactions
- 24 Mar 2021 Status changed from recruiting to completed.
- 02 Jul 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 02 Jul 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.